{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:26:16Z","timestamp":1787235976728,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bone.2025.117407","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T12:38:59Z","timestamp":1737635939000},"page":"117407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Parathyroid hormone levels following denosumab vs. zoledronic acid therapy for osteoporosis"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6029-7593","authenticated-orcid":false,"given":"Pnina","family":"Rotman-Pikielny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Barzilai-Yosef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erez","family":"Ramaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Braginski-Shapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal Kasher","family":"Meron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzipi Hornik","family":"Lurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2025.117407_bb0005","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for the prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2025.117407_bb0010","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5\u00a0years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2025.117407_bb0015","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"HORIZON pivotal fracture trial","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2025.117407_bb0020","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bone.2025.117407_bb0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2025.117407_bb0030","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s00774-022-01331-9","article-title":"The relationship between chronic kidney disease and denosumab-induced hypocalcemia in high-age osteoporotic patients","volume":"40","author":"Horikawa","year":"2022","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2025.117407_bb0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13256-023-03764-w","article-title":"Denosumab-induced hypocalcemia post bariatric surgery\u2014a severe and protracted course: a case report","volume":"17","author":"Awang","year":"2023","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.bone.2025.117407_bb0040","doi-asserted-by":"crossref","first-page":"116298","DOI":"10.1016\/j.bone.2021.116298","article-title":"Tolerability of the first infusion of once-yearly zoledronic acid within one to two weeks after hip fracture surgery","volume":"155","author":"Kashii","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.bone.2025.117407_bb0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4158\/EP.12.1.48","article-title":"Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature","volume":"12","author":"Maalouf","year":"2006","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.bone.2025.117407_bb0050","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117407_bb0055","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cen.12188","article-title":"Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis","volume":"79","author":"Makras","year":"2013","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.bone.2025.117407_bb0060","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/jc.2015-4181","article-title":"Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study","volume":"101","author":"Dempster","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117407_bb0065","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12902-015-0077-3","article-title":"Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study","volume":"15","author":"Nakamura","year":"2015","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.bone.2025.117407_bb0070","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1210\/clinem\/dgz138","article-title":"Preventive role of vitamin D supplementation for acute phase reaction after bisphosphonate infusion in Paget\u2019s disease","volume":"105","author":"Merlotti","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2025.117407_bb0075","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00198-019-05261-7","article-title":"Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?","volume":"31","author":"Tsvetov","year":"2020","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2025.117407_bb0080","unstructured":"Prolia (denosumab) package insert. 2015. https:\/\/www.pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/prolia\/prolia_pi.pdf; https:\/\/www.pi.amgen.com>prolia>prolia_pi."},{"key":"10.1016\/j.bone.2025.117407_bb0085","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/pds.4045","article-title":"Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting","volume":"25","author":"Huynh","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.bone.2025.117407_bb0095","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1016\/j.bone.2012.02.507","article-title":"Association between transitory increase in PTH following denosumab administration and reduced intracortical porosity is a distinctive attribute of denosumab therapy","volume":"50","author":"Seeman","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.bone.2025.117407_bb0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1210\/endrev\/bnab005","article-title":"Physiological and pharmacological roles of PTH and PTHrP in bone using their shared receptor, PTH1R","volume":"42","author":"Martin","year":"2021","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2025.117407_bb0105","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00223-014-9840-0","article-title":"Vitamin D status and parathyroid hormone concentrations influence the skeletal response to zoledronate and denosumab","volume":"94","author":"Mosali","year":"2014","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2025.117407_bb0110","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","article-title":"Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone","volume":"19","author":"Ferrari","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bone.2025.117407_bb0115","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos. Int."},{"issue":"Suppl. 4","key":"10.1016\/j.bone.2025.117407_bb0120","first-page":"3","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology: clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis","volume":"22","author":"Camacho","year":"2016","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.bone.2025.117407_bb0125","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2002-020275","article-title":"Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women","volume":"87","author":"Tannenbaum","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225000195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225000195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:40:55Z","timestamp":1777275655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328225000195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":24,"alternative-id":["S8756328225000195"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2025.117407","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parathyroid hormone levels following denosumab vs. zoledronic acid therapy for osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2025.117407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117407"}}